Immusoft Awarded $15M in Funding from the California Institute for Regenerative Medicine

Immusoft has received $15M from the California Institute for Regenerative Medicine to further develop ISP-001, its therapy for the rare disease mucopolysaccharidosis type I. Early trials show the treatment is safe, well-tolerated, and improves patient function, with successful re-dosing suggesting it could provide long-term benefits for those with this serious condition.